Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 1/20 | 0.55 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.55 |
| ▸ | PTGER4 | P35408 | 6/20 | 0.51 |
| ▸ | PTGER2 | P43116 | 6/20 | 0.51 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | GCK | P35557 | 1/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11299022 | 1.00 | LTB4R (0.55) | LTB4RLTB4R2PTGER4PTGER2PTGER3 | |
| SCHEMBL20750979 | 0.90 | LTB4R (0.53) | LTB4RLTB4R2PTGER4PTGER2PTGER3 | |
| SCHEMBL9204585 | 0.85 | LTB4R (0.69) | LTB4RLTB4R2PTGER4PTGER2PTGER3 | |
| SCHEMBL9204592 | 0.85 | LTB4R (0.69) | LTB4RLTB4R2PTGER4PTGER2PTGER3 | |
| SCHEMBL9205735 | 0.81 | LTB4R (0.58) | LTB4RLTB4R2PTGER4PTGER2PTGER3 | |
| SCHEMBL9205737 | 0.81 | LTB4R (0.58) | LTB4RLTB4R2PTGER4PTGER2PTGER3 | |
| SCHEMBL3725341 | 0.76 | KDM4E (0.52) | LTB4RLTB4R2KDM4ELMNAALOX5 | |
| SCHEMBL3725344 | 0.76 | KDM4E (0.52) | LTB4RLTB4R2KDM4ELMNAALOX5 | |
| SCHEMBL3817639 | 0.76 | FFAR4 (0.55) | PTGER4PTGER2PTGER3PTGER1KDM4E | |
| SCHEMBL28424630 | 0.76 | PTGER4 (0.43) | LTB4RLTB4R2PTGER4PTGER2PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3443957-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | LIMINAL BIOSCIENCES LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| EP-3443957-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC PHARMA SMT LIMITED (GB) | 2019-02-20 | — | — | EP | disclosed |
| EP-2632452-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC PHARMA SMT LTD (GB) | 2018-09-26 | — | — | EP | disclosed |
| US-9439882-B2 | Compounds and compositions for the treatment of cancer | PROMETIC BIOSCIENCES INC. (CA) | 2016-09-13 | — | — | US | disclosed |
| US-20150313856-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC PHARMA SMT LIMITED (GB) | 2015-11-05 | — | — | US | disclosed |
| US-9114118-B2 | Compounds and compositions for the treatment of cancer | PROMETIC BIOSCIENCES INC. (CA) | 2015-08-25 | — | — | US | disclosed |
| EP-2632452-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ProMetic BioSciences Inc. (CA) | 2013-09-04 | — | — | EP | disclosed |
| US-20130217645-A1 | Compounds and Compositions for the Treatment of Cancer | PROMETIC BIOSCIENCES INC. (CA) | 2013-08-22 | — | — | US | disclosed |
| WO-2012097427-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC BIOSCIENCES INC. (CA) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217645-A1 | Compounds and Compositions for the Treatment of Cancer | DCK, TOP2B, TOP2A | LTB4R 4712/4885LTB4R2 4356/4885PTGER4 2063/4885 |
| US-20150313856-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | DCK, TOP2B, TOP2A | LTB4R 4712/4885LTB4R2 4356/4885PTGER4 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.